AO: Fresenius: Fresenius Stock Trader Recommendations | FRE | DE0005785604

Barclays Capital (BarCap) downgraded its recommendation on Fresenius to online weighting & # 39; with overweight & # 39; and reduced its target price by 70 to 51 euros, following reduced earnings estimates of 7-11% for the dialysis specialist.

"If we think Fresenius's preliminary 2019 targets are likely to be conservative, potential changes in Germany's hospital price regulation in 2020 allow us to expect a potential downside," says BarCap.

The broker adopts a more cautious view of the title, despite the appreciation and vigor of Kabi, awaiting execution and more clarity before considering a more constructive view – on record.

Copyright (c) 2019 CercleFinance.com. All rights reserved
The information and analyzes disclosed by Cercle Finance are only an aid to investors' decisions. Cercle Finance's liability can not be withheld directly or indirectly after the use of information and analysis by readers. It is recommended that any uninformed person consult a professional consultant before investing. This indicative information does not in any way constitute an incentive to sell or a solicitation to buy.